Skip to content
FDAMedical devicesClass IIOngoing

FDA recall 99214: Siemens Healthcare Diagnostics, Inc.: Atellica CH Enzymatic Hemoglobin A1c

FDA recall 99214 ·

Build snapshot. Collected , once, when this site was built. It is not a live feed.

Check my lot or code

Is yours in this recall?

Type the lot, batch, date code, model number or UPC printed on the product. It is compared here, in your browser, with the codes this notice lists. It stays in this page: it is not added to the address.

General information on recalls from the agency: U.S. Food and Drug Administration (opens in a new tab).

What the agency says to do

FDA’s record gives no instruction for consumers.

Status: Ongoing. What the FDA’s recall statuses mean (opens in a new tab)

Note from Recalls Watch, not agency text

Why it was recalled

The potential for intermittent well-to-well bias on the A1c_E assay on the Atellica CH and Atellica CI analyzer which could cause falsely depressed or falsely elevated HbA1c patient results.
Text from FDA, unedited.

FDA classification: Class II. What the FDA’s classes mean (opens in a new tab)

The recalled product

Codes in the record. Click one to copy it.

  • Atellica CH Enzymatic Hemoglobin A1c (A1c_E). Material Number: 11097536.

    Lot or code
    Material Number: 11097536. UDI-DI: 00630414220505. All Lot Numbers.
    FDA recall number
    Z-2703-2026
    Quantity
    24,077 units

Distribution (FDA): Worldwide distribution - US Nationwide and the countries of Argentina, Australia, Austria, Bahamas, Bangladesh, Bolivia, Brazil, Bulgaria, Burkina¿Faso, Canada, Chile, China, Colombia, Croatia, Cura¿ao,¿St¿Eus, Czech¿Republic, Democratic Republic Congo, Denmark, Ecuador, Egypt, El Salvador, Estonia, Finland, France, Georgia, Germany, Greece, Hong Kong, India, Indonesia, Israel, Italy, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Lithuania, Macedonia, Malaysia, Mexico, Netherlands, New Zealand, Norway, Oman, Pakistan, Paraguay, Poland, Portugal, Qatar, Republic of Korea, Romania, Saudi¿Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Switzerland, Thailand, Turkey, Turkmenistan, U.A.E., Uganda, United¿Kingdom, Uruguay, Vatican City, Vietnam.

Source

Issued by
U.S. Food and Drug Administration
Firm
Siemens Healthcare Diagnostics, Inc.
Title
Composed by Recalls Watch from fields of the record; FDA records have no title.

Check all notices that name this firm in the directory of recalls by brand and manufacturer. This notice is in these lists: Firm: Siemens Healthcare Diagnostics, Inc., Month: July 2026, Week 2026-W29. Browse more medical devices recalls, or check another notice by its number in the recall number lookup.

About this recall

What is the hazard?

FDA states: “The potential for intermittent well-to-well bias on the A1c_E assay on the Atellica CH and Atellica CI analyzer which could cause falsely depressed or falsely elevated HbA1c patient results.”

What should I do if I have this product?

FDA’s record gives no instruction for consumers. The official report is linked on this page.

How do I know if my product is included?

Compare the lot or code printed on your product with the codes FDA lists on this notice, product by product.

How does the code check on this page work?

You type the lot, batch, date code, model number or UPC from your package and the page compares it, in your browser, with the codes FDA lists on this notice. It reports a match, a possible match (your code is part of a longer listed code) or no match. It only compares text: a notice that describes products by dates, sizes or “all lots” cannot be compared, so “no match” does not clear a product. The comparison runs in your browser and the page does not send the code anywhere, and the code stays out of the page address. Only if you press “Copy link to this result” is a link made that carries it, and whoever opens that link requests that address from this site.

When was this recall published?

FDA published recall 99214 on July 15, 2026.

Other notices of Siemens Healthcare Diagnostics, Inc.